Temozolomide

Generic Name
Temozolomide
Brand Names
Temodar, Temomedac, Temodal, Temozolomide Sun, Temozolomide Accord, Temozolomide Teva
Drug Type
Small Molecule
Chemical Formula
C6H6N6O2
CAS Number
85622-93-1
Unique Ingredient Identifier
YF1K15M17Y
Background

Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably ...

Indication

Temozolomide is indicated in adult patients for the treatment of newly diagnosed glioblastoma concomitantly with radiotherapy and for use as maintenance treatment thereafter. It is also indicated for the treatment of refractory anaplastic astrocytoma in adult patients or adjuvant therapy for adults with newly diagnosed anaplastic astrocytoma.

Associated Conditions
Advanced Melanoma, High Grade Glioma: Glioblastoma (GBM), Primary Central Nervous System Lymphoma, Refractory Ewing Sarcoma, Refractory Neuroblastoma, Soft Tissue Sarcoma, Advanced Neuroendocrine tumor, Newly diagnosed Anaplastic Astrocytoma (AA), Refractory Anaplastic astrocytoma, Refractory, advanced Mycosis fungoides, Refractory, advanced Sezary Syndrome
Associated Therapies
-
Clinical Trials
Related News

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

First Posted Date
2021-09-10
Last Posted Date
2024-08-16
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
141
Registration Number
NCT05040360
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

🇺🇸

Los Angeles County-USC Medical Center, Los Angeles, California, United States

🇺🇸

University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States

and more 316 locations

Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy

First Posted Date
2021-09-02
Last Posted Date
2022-09-02
Lead Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Target Recruit Count
35
Registration Number
NCT05031975
Locations
🇮🇹

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, MI, Italy

Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial

First Posted Date
2021-09-01
Last Posted Date
2024-10-31
Lead Sponsor
Mayo Clinic
Target Recruit Count
25
Registration Number
NCT05030298
Locations
🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer

First Posted Date
2021-07-30
Last Posted Date
2023-11-29
Lead Sponsor
University of Southampton
Target Recruit Count
18
Registration Number
NCT04984733
Locations
🇬🇧

Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom

Newly Diagnosed Glioblastoma

First Posted Date
2021-07-13
Last Posted Date
2021-07-13
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
150
Registration Number
NCT04959500
Locations
🇨🇳

Chongqing University Cancer Hospital, Chongqing, Chongqing Province, China

🇨🇳

Lanzhou University Second Hospital, Lanzhou, Gansu, China

🇨🇳

Shenzhen People's Hospital, Shenzhen, Guangdong, China

and more 18 locations

Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide

First Posted Date
2021-06-30
Last Posted Date
2024-07-31
Lead Sponsor
Hopital Foch
Target Recruit Count
640
Registration Number
NCT04945148
Locations
🇫🇷

Foch Hospital, Suresnes, Hauts De Seine, France

🇮🇹

Spidali Riuniti Di Livorno, Livorno, Toscana Nord Ouest, Italy

🇫🇷

Pitié Salpêtrière Hospital, Paris, France

and more 4 locations

Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

First Posted Date
2021-06-09
Last Posted Date
2024-09-27
Lead Sponsor
Dwight Owen
Target Recruit Count
56
Registration Number
NCT04919382
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

🇺🇸

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States

🇺🇸

University of Illinois Cancer Center, Chicago, Illinois, United States

and more 2 locations

Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

First Posted Date
2021-06-02
Last Posted Date
2024-12-03
Lead Sponsor
Nerviano Medical Sciences
Target Recruit Count
150
Registration Number
NCT04910022
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

🇺🇸

Mayo Clinic Hospital - Phoenix, Phoenix, Arizona, United States

🇺🇸

Mayo Clinic Florida, Jacksonville, Florida, United States

and more 8 locations

A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

First Posted Date
2021-05-25
Last Posted Date
2024-12-10
Lead Sponsor
Bryan Allen
Target Recruit Count
12
Registration Number
NCT04900792
Locations
🇺🇸

Department of Radiation Oncology at University of Iowa, Iowa City, Iowa, United States

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

First Posted Date
2021-05-25
Last Posted Date
2024-06-17
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
46
Registration Number
NCT04901702
Locations
🇺🇸

Lucille Packard Children's Hospital Stanford, Palo Alto, California, United States

🇺🇸

Children's Hospital Colorado, Aurora, Colorado, United States

🇺🇸

Children's Healthcare of Atlanta/Emory University School of Medicine, Atlanta, Georgia, United States

and more 7 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy